Red Light Therapy for Autism & Seizures

Autism spectrum disorder (ASD) affects roughly 1 in 100 people in the UK. It is a neurodevelopmental condition — not a disease to be cured — characterised by differences in social communication, sensory processing, and behaviour. Many autistic individuals also experience co-occurring challenges: sleep disruption, anxiety, irritability, and in approximately 20–30% of cases, epilepsy or seizures.

Current pharmaceutical options for these co-occurring symptoms carry significant side effects, particularly in children. That context explains the growing interest in photobiomodulation (PBM) — red and near-infrared light therapy — as a potential supportive intervention. But interest is not evidence. Here is what the research actually shows.

The biological rationale

The theoretical basis for PBM in autism rests on three observations from neuroscience research.

Mitochondrial dysfunction

A substantial body of evidence links ASD to mitochondrial dysfunction. Rossignol and Frye (2012) published a meta-analysis identifying mitochondrial disease in roughly 5% of autistic individuals, with a much larger proportion showing biomarkers of impaired mitochondrial function. PBM’s primary mechanism — stimulating cytochrome c oxidase in the mitochondrial electron transport chain — directly targets this pathway.

Neuroinflammation

Post-mortem studies and neuroimaging research have consistently found elevated neuroinflammation in autistic brains. Vargas et al. (2005) identified active neuroglial responses and elevated cytokine levels in brain tissue from autistic individuals. Transcranial PBM has been shown to reduce neuroinflammation in animal models (Hamblin, 2018), which provides a plausible — if unproven — mechanism for benefit.

Cerebral blood flow

Several studies have documented reduced cerebral perfusion in specific brain regions in ASD, particularly the temporal lobes and prefrontal cortex. Transcranial PBM has been shown to increase cerebral blood flow in healthy adults (Salgado et al., 2015), and this effect could theoretically benefit areas of relative hypoperfusion.

None of this proves PBM helps autistic individuals. It establishes biological plausibility — nothing more.

What the clinical evidence shows

The honest answer is: very little, but what exists is cautiously interesting.

Ceranoglu et al. (2022) — the most cited work

The most relevant clinical data comes from Ceranoglu and colleagues at Massachusetts General Hospital, who published a case series examining transcranial PBM in children and adolescents with ASD. Using near-infrared light (810 nm) applied to the forehead and temporal regions, they reported improvements in irritability, social withdrawal, and repetitive behaviours as measured by the Aberrant Behavior Checklist (ABC).

That said, this was an open-label case series with no control group. The improvements could reflect placebo response, natural developmental progress, or the simple effect of regular clinical attention. The authors themselves called for randomised controlled trials.

Leisman et al. — transcranial PBM and neurodevelopment

Leisman and colleagues have contributed broader work on transcranial photobiomodulation and neurodevelopmental conditions. Their research has explored how PBM may influence cortical connectivity and cerebellar function — both relevant to ASD. However, much of this work remains theoretical or based on small pilot studies rather than definitive clinical trials.

Hamblin — the mechanistic foundation

Michael Hamblin’s extensive body of work on transcranial PBM provides the mechanistic backbone for this field. His reviews (Hamblin, 2016; 2018) document PBM’s effects on mitochondrial function, oxidative stress, and neuroinflammation across multiple neuropsychiatric conditions. While not autism-specific, this work underpins the rationale for every transcranial PBM trial in neurodevelopmental and neuropsychiatric contexts.

Cassano et al. — neuropsychiatric PBM

Cassano and colleagues at Harvard/MGH have conducted multiple trials of transcranial PBM for depression and anxiety — conditions that frequently co-occur with ASD. Their work (Cassano et al., 2016; 2018) demonstrates that transcranial PBM can modulate brain function and improve psychiatric symptoms in adults. This is relevant because it suggests PBM can cross the skull and produce measurable neurological effects, but it does not directly address autism.

Animal studies

Several rodent studies have examined PBM in models of ASD-like behaviour. Zhuo et al. (2022) reported improved social behaviour and reduced repetitive behaviours in a valproic acid-induced autism mouse model following PBM treatment. Animal models of ASD have obvious limitations, but they add to the biological plausibility argument.

The seizure question — a serious consideration

This is where caution becomes critical.

Approximately 20–30% of autistic individuals experience seizures or have epileptiform activity on EEG. Any intervention that modulates neural activity raises a legitimate question: could it lower the seizure threshold?

What we know: There is no published evidence that PBM triggers seizures. In fact, some animal research suggests PBM may have anticonvulsant properties — Radwan et al. (2009) reported reduced seizure severity in a pentylenetetrazol-induced epilepsy model following near-infrared light application.

What we do not know: Whether transcranial PBM at the intensities and wavelengths commonly used could provoke seizures in susceptible individuals. The absence of reported adverse events is not the same as established safety. Most PBM studies have explicitly excluded participants with epilepsy, so the relevant population has barely been studied.

The practical position: If you or your child has a history of seizures, febrile convulsions, or epileptiform EEG activity, do not attempt transcranial PBM without explicit guidance from a neurologist. This is not an area where self-experimentation is appropriate.

Protocol considerations

Given the limited clinical evidence, any protocol recommendations come with heavy caveats. The following is based on parameters used in the published research, not on established clinical guidelines — because none exist.

Wavelength

• 810 nm (near-infrared): The most commonly used wavelength in transcranial PBM research, including the Ceranoglu case series. NIR at this wavelength penetrates the skull more effectively than red light.
• 670 nm (red): Less skull penetration but still used in some protocols, particularly for surface-level effects.

Delivery

• Transcranial application to the forehead (prefrontal cortex) and temporal regions
• Published protocols typically use LED clusters or low-level laser devices
• Treatment duration: 10–20 minutes per session in most studies
• Frequency: 2–3 sessions per week in clinical studies

Power density

• Transcranial studies typically target 10–50 mW/cm² at the scalp surface
• Higher is not better — the biphasic dose response (Huang et al., 2009) means excessive dosing can negate benefits

Important caveats

• No regulatory body has approved PBM for autism
• These parameters are drawn from early-stage research, not clinical guidelines
• Children’s skulls are thinner — power density calculations differ from adult protocols
• Sensory sensitivities common in ASD mean that device noise, warmth, or light may cause distress

Who should not use red light therapy for autism

• Anyone with active epilepsy or a history of seizures — not without neurologist approval
• Anyone on photosensitising medication — some anticonvulsants increase photosensitivity
• Anyone who finds the experience distressing — forcing a sensory-averse child through light therapy sessions is counterproductive and ethically questionable
• Anyone expecting it to replace evidence-based interventions — PBM is not a substitute for speech therapy, occupational therapy, educational support, or prescribed medication

Frequently asked questions

Can red light therapy cure autism?

No. Autism is a neurodevelopmental difference, not a disease with a cure. PBM research in this area targets co-occurring symptoms — irritability, sleep disruption, anxiety — not the core condition itself. Be deeply sceptical of any provider claiming otherwise.

Is it safe for children?

There is no evidence of harm from PBM at appropriate doses in children, but there is also very limited safety data specific to paediatric use. The thinner skull in children means brain tissue receives higher irradiance for a given surface power density. Any paediatric use should involve medical supervision.

Which home devices work for transcranial PBM?

Most consumer red light therapy panels are designed for skin and musculoskeletal use, not transcranial application. Dedicated transcranial PBM devices exist (e.g., Vielight), but their clinical validation for autism is minimal. This is not a recommendation — it is context.

How long before seeing results?

The Ceranoglu case series reported changes over 8–12 weeks of consistent treatment. However, without controlled data, it is impossible to separate genuine treatment effects from other variables.

The bottom line

The biological rationale for PBM in autism is genuinely plausible. Mitochondrial dysfunction, neuroinflammation, and cerebral hypoperfusion are real features of ASD, and PBM has demonstrated effects on all three — in other contexts. The early clinical data from Ceranoglu and others is interesting enough to warrant proper randomised controlled trials.

But that is where we are: at the warrant-further-study stage. Not at the recommend-to-patients stage.

If you are a parent exploring options for your autistic child, the honest picture is this: PBM is unlikely to cause harm at sensible doses (with the critical exception of seizure-prone individuals), but the evidence that it helps is preliminary at best. It should sit alongside — never instead of — established supports like speech therapy, OT, and educational accommodations.

If your child has co-occurring epilepsy, the risk-benefit calculation changes significantly. Speak to your neurologist before considering any form of transcranial stimulation.

The field needs larger, controlled trials with autistic participants. Until those exist, PBM for autism remains a hypothesis with interesting early signals — not an evidence-based treatment.